AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05541016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and saliva specimen collection for NavDx testing
Study NCT05541016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT05541016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05541016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05541016 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diffusing Alpha-emitter Radiation Therapy
Description: Undergo DART
Study NCT05541016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT05541016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Proton Therapy
Description: Undergo IMPT
Study NCT05541016 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT05541016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05541016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05541016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Barium Swallow Study
Description: Undergo MBSS
Study NCT05541016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Barium Swallow Study
Description: Undergo MBSS
Study NCT05541016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Undergo observation
Study NCT05541016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT05541016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT05541016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05541016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05541016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Ancillary studies
Study NCT05541016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies
Study NCT05117892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training, certification and marketing scheme
Description: The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
Study NCT06339593 — intervention group
Intervention type: DRUG
Intervention: Hyperpolarized Xe129
Description: Hyperpolarized Xe MRI is FDA Approved for Adults and Children 12 and above We have been performing Xe MRI for research in human subjects for over 20 years, and for over 10 years at CCHMC. Recent FDA approval of hyperpolarized Xe MRI for ventilation stands as a testament to its safety and value as a modern tool for exploring lung disease and function. Earlier studies using Xe MRI have shown its efficacy in exploring CF and other lung diseases in pediatric and adult populations, and it has been found to be much more sensitive to early lung disease than traditional metrics like spirometry and MBW
Study NCT06158984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL
Description: Intense pulse light (IPL) therapy is used for the treatment of drug-related dry eye in glaucoma patients.
Study NCT05919693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE103
Description: EYE103 is a humanized antibody formulated for IVT administration
Study NCT04616287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological assessment and Multimodal brain MRI
Description: Neuropsychological assessment and Multimodal brain MRI
Study NCT04616287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment and Multimodal brain MRI
Description: Neuropsychological assessment and Multimodal brain MRI
Study NCT04616287 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neuropsychological assessment and Multimodal brain MRI
Description: Neuropsychological assessment and Multimodal brain MRI
Study NCT05352802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program
Description: Multimodal prehabilitation programs have adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.
Study NCT05352802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ERAS protocol
Description: The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
Study NCT05352802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
Study NCT06225167 — intervention group
Intervention type: BEHAVIORAL
Intervention: To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.
Description: To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.~To compare the incidence of overt GI bleeds (defined as hematemesis, bloody nasogastric tube aspirate, or melena) between patients who were on stress ulcer prophylaxis versus patients whose acid suppression therapy was discontinued through the stress ulcer prophylaxis minimization protocol.
Study NCT05621486 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B4T2-001 Autologous CAR T cells
Description: Each subject will receive infusion with B4T2-001 autologous CAR T Cells
Study NCT05351255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Aim 2 of the study includes an intervention where participants receive a repetitive TMS protocol called theta burst stimulation (TBS) to study its effect on motor learning behavior.
Study NCT03244072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Intracameral injection
Study NCT03244072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intracameral injection
Study NCT05671289 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: analysis of urine volatile organic compounds
Description: gas chromatography - mass spectrometry will be used to assess the composition of VOCs in urine samples of all participants.
Study NCT05030779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Assigned Interventions CD19/BCMA CAR T-cells
Description: Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
Study NCT06444906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermacyte Matrix
Description: The appropriate square centimeters of Dermacyte Matrix is applied directly to the target DFU that is free of debris and necrotic tissue. The Dermacyte Matrix will be applied at weekly intervals or for up to 10 applications.
Study NCT06444906 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SOC)
Description: SOC therapy will consist of debridement of nonviable tissue, saline-moistened non-occlusive dressing, weight off-loading to decrease pressure on extremity, aggressive treatment of infection and arterial revascularization if indicated at weekly intervals or for up to 10 applications.
Study NCT05239130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auralya
Description: Auralya® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation. Auralya® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile glass syringe with a Luer adapter.
Study NCT05014386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Glaucoma Valve Implantation in secondary pediatric glaucomas.
Description: A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
Study NCT05014386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Glaucoma Valve Implantation with Ologen augmentation in secondary pediatric glaucomas
Description: A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. a round 12 × 1 mm circular Ologen disc will be placed over the FP7 or FP8 AGV-plate immediately before conjunctival closure. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
Study NCT04498130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-Week Home Exercise Group
Description: 12 week home-based program consisting of: weekly Zoom group chats; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page
Study NCT04498130 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Comparison Group
Description: 12 week home-based program consisting of: weekly check-in phone calls; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page.
Study NCT04296695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: randomized, multicentered, open-lable RCT, one arm with B/F/TAF and one arm with TDF/3TC/EFV
Study NCT04296695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/3TC/EFV
Description: TDF/3TC/EFV
Study NCT06243354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test product: HYP-2090PTSA
Description: Dosage form: Capsule. Strength: 2.5 mg, 5 mg. Method of administration: Oral; Dose escalation: a fixed dose QD is planned, and all other dose levels and administration methods are temporary with the exception of the initial dose. Dose expansion: the dose and method of administration are conducted as discussed by the sponsor and investigators.~Medication cycle: Take orally under fasting condition every morning, with 21 days as a cycle (tentative), and continue taking until disease progression, or intolerable toxicity, or withdrawal of informed consent, or treatment with another antitumor drug, or the death of the subject, or loss to follow-up (whichever occurs earliest).
Study NCT03035838 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fosaprepitant
Description: Within 24 hours from injury, IVAMEND (the intravenous formulation of the NK-1 antagonist fosaprepitant) will be administered at a dose of 300 mg, intravenously over 1 hour.
Study NCT06311279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior resection of Rectal cancer
Description: Anterior resection of cancer rectum and type of anastomosis (End to end or side to end)
Study NCT05653713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL324
Description: Single intravenous (IV) dose of CSL324
Study NCT05653713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV dose of 0.9% saline
Study NCT03814109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LENINGRADO association
Description: 1 coated sustained-release tablet, oral, once a day.
Study NCT03814109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide SR 1.5 MG
Description: 1 coated sustained-release tablet, oral, once a day.
Study NCT03814109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levamlodipine 2.5/ 5 mg
Description: 1 tablet, oral, once a day.
Study NCT03814109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leningrado association Placebo
Description: 1 coated sustained-release tablet, oral, once a day.
Study NCT04861857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Parmigiano Reggiano
Description: subjects will receive 50 g/die of the dietary supplement
Study NCT03814109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indapamide SR Placebo
Description: 1 coated sustained-release tablet, oral, once a day.
Study NCT03814109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide SR Placebo
Description: 1 coated sustained-release tablet, oral, once a day.
Study NCT03814109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Levamlodipine placebo
Description: 1 tablet, oral, once a day.
Study NCT03814109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Levamlodipine placebo
Description: 1 tablet, oral, once a day.
Study NCT04861857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: subjects will receive 20 g/die of the dietary supplement
Study NCT05024851 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Evaluation of the Psychogenic and Neurogenic Components using questionnaires
Study NCT04826601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: essential oils
Description: A total of 40 cancer patients receiving chemotherapy will be recruited as participants in this study. Blood orange and rosewood will be chosen as the essential oils for aromatherapy in this study. Essential oils will be applied to all participants by inhalation for 30 minutes.
Study NCT06385743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training-based Exercise Program
Description: Neuromuscular training has been accepted as an effective treatment modality to improve the neurophysiological states of the joints for coordinated work. In addition to shoulder strength, stabilization and kinetic chain exercises, this program includes internal and external focus (sound, touch, light, dual task, etc.), sport-specific exercises and plyometric exercises (speed, agility). All athletes with shoulder pain will include in the baseline evaluation at the beginning of the season and all parameters will be followed throughout the season for 8 weeks. All athletes in this group will participate in a total of 24 physiotherapy sessions, 3 days a week, for eight weeks.
Study NCT06385743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ''Thrower's Ten'' Exercise Program
Description: ''Thrower's Ten'' Exercise Program includes 10 different shoulder strengthening and shoulder stabilization exercises in a diagonal pattern. Advanced Thrower's Ten exercises that include kinetic chain exercises (covering more than one joint) in addition to shoulder exercises planned to be used in the late stages of rehabilitation into the program, progression is considered after the 3rd week will be added. All athletes with shoulder pain will include in the baseline evaluation at the beginning of the season and all parameters will be followed throughout the season for 8 weeks. All athletes in this group will participate in a total of 24 physiotherapy sessions, 3 days a week, for eight weeks.
Study NCT04666766 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave scanning of the head
Description: A scan of the head will be performed with a microwave device to ascertain the likelihood of intracranial hemorrhage.
Study NCT04679402 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Carbon monoxide 200 ppm in air
Description: Low dose carbon monoxide
Study NCT04679402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon monoxide 200 ppm in air
Description: Low dose carbon monoxide
Study NCT04584034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol will be delivered using a Babyhaler spacer device. Ventolin will be used, brandname for Salbutamol sulfate. Ventolin contains the propellant HFA 134a.
Study NCT04584034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be delivered using a Babyhaler spacer device. The placebo will contain only the propellant HFA 134a.
Study NCT05009147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based massage by caregivers for dementia
Description: A total of 40 patients with dementia and their family caregivers will be included and randomly allocated to experiment (n=20) or control group (n=20). The experiment and control group will receive whole body manual massage and placebo intervention (30 minutes once per week for 8 continuous weeks), respectively.
Study NCT05892068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Standard dose of 300mg orally twice daily for 4 days prior to surgery (day -4 to 0).
Study NCT04499807 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AFib detection with wearable smart watch
Description: Patients will transmit two rhythm strips every day through both the devices and additional transmission whenever they have symptoms (palpitations, skipped beats, shortness of breath and chest pain). The transmitted rhythm strips are de-identified and analyzed after assigning a unique ID for research purposes.
Study NCT05518656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Description: Daily lessons received by email to be completed the same day
Study NCT05518656 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison intervention
Description: Daily lessons receive by email to be completed the same day
Study NCT06248918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WATSOCPAP
Description: Participants will receive an supervised and individualized exercise plan, activity tracker, and physical activity coaching program based Social Cognitive Theory. Participants will be administered strengthening and aerobic exercise program, structured and individualized according to the person's individual capacity and needs, under the supervision of a physiotherapist. The activity tracker will provide real-time activity information about daily steps, time spent with MVPA (minutes/day) and sedentary time. The nurse-led physical activity coaching program was planned according to the Social Cognitive Theory (SCT) components such as self-regulation, outcome expectation, social support and perceived environment. The interventions will continue with online and the 12-week program will be completed.
Study NCT05596643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Composite Autonomic Symptom Score-31
Description: Standardized questionnaire to determine the level of autonomic dysfunction
Study NCT05596643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: r-r interval variability with normal breathing
Description: electrophysiological test to detect parasympathetic dysfunction
Study NCT05596643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: r-r interval variability with deep breathing
Description: electrophysiological test to detect parasympathetic dysfunction
Study NCT05596643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Valsalva ratio
Description: electrophysiological test to detect parasympathetic dysfunction
Study NCT05596643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 30:15 ratio
Description: electrophysiological test to detect parasympathetic dysfunction
Study NCT05596643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sympathetic skin response
Description: electrophysiological test to detect sympathetic dysfunction